• CareDx (CDNA +10.6%) is up on modestly higher volume in reaction to the release of final local coverage determination by Medicare administrator Palmetto MolDx for AlloSure Heart, a donor-derived cell-free DNA (cfDNA) test that identifies underlying cell injury leading to organ rejection.
• The company says the coverage decision paves the way for patient/provider availability of HeartCare, the combination of AlloSure Heart and AlloMap Heart, an 11-gene panel that detects changes in gene expression associated with acute organ rejection.
• https://seekingalpha.com/news/3618887-caredx-up-11-on-medicare-coverage-of-organ-rejection-test